论文部分内容阅读
目的检测细胞角蛋白(CK)19、上皮膜抗原(EMA)、高分子量细胞角蛋白(34βE12)和CK7在甲状腺乳头状微小癌(PTMC)和甲状腺良性病变中的表达情况,以提高PTMC的诊断和鉴别诊断水平。方法应用免疫组织化学SP法检测43例PTMC和47例甲状腺良性病变中CK19、EMA、34βE12和CK7的表达。结果CK19、EMA、34βE12、CK7在PTMC中的表达率分别为93.02%、90.70%、88.37%、95.35%,在良性甲状腺病变中极少表达,表达率分别为4.26%、10.64%、8.51%、21.28%,差异均有统计学意义(P<0.05)。结论CK19、EMA、34βE12和CK7在PTMC的病理诊断和鉴别诊断中具有重要意义。
Objective To detect the expression of cytokeratin 19, epithelial membrane antigen (EMA), high molecular weight cytokeratin (34βE12) and CK7 in benign thyroid papillary carcinoma (PTMC) and thyroid benign lesions in order to improve the diagnosis of PTMC And differential diagnosis level. Methods The expressions of CK19, EMA, 34βE12 and CK7 in 43 cases of PTMC and 47 cases of thyroid benign lesions were detected by immunohistochemical SP method. Results The positive rates of CK19, EMA, 34βE12 and CK7 in PTMC were 93.02%, 90.70%, 88.37% and 95.35%, respectively. The expression rates of CK19, EMA, 34βE12 and CK7 were extremely low in benign thyroid lesions. The positive rates were 4.26%, 10.64%, 8.51% 21.28%, the differences were statistically significant (P <0.05). Conclusion CK19, EMA, 34βE12 and CK7 are of great significance in the pathological diagnosis and differential diagnosis of PTMC.